(Q36117060)

12 August 2017

1 reference

title

Vaccinia recombinants as vaccine vectors (English)

1 reference

12 August 2017

Mahr A

1

1 reference

12 August 2017

Payne LG

series ordinal

2

1 reference

12 August 2017

publication date

1 February 1992

1 reference

12 August 2017

1 reference

12 August 2017

volume

184

1 reference

12 August 2017

issue

2-3

1 reference

12 August 2017

page(s)

126-146

1 reference

Construction of an adenovirus-SV40 recombinant producing SV40 T antigen from an adenovirus late promoter

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Expression of SV40 T antigen under control of adenovirus promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Vaccinia virus: a selectable eukaryotic cloning and expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

The complete DNA sequence of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Recognition by major histocompatibility complex class I-restricted cytolytic T lymphocytes of cells expressing vaccinia-encoded viral and class I proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Efficient targeted insertion of an unselected marker into the vaccinia virus genome

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Mapping of a vaccinia host range sequence by insertion into the viral thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Localization and sequence of a vaccinia virus gene required for multiplication in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Host range deletion mutant of vaccinia virus defective in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Complications of smallpox vaccination, 1968.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Deletion of the vaccinia virus growth factor gene reduces virus virulence

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Vaccinia virus vectors: new strategies for producing recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Expression of rabies virus glycoprotein from a recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Expression of AIDS virus envelope gene in recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Expression of the HTLV-III envelope gene by a recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

AIDS vaccine therapy: phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980471-7

7 January 2021

10.1016/S0171-2985(11)80471-7

Identifiers

DOI

0 references

1 reference